Pharm: Neurodegenerative, movement disorders, and anti-epileptic Drugs Flashcards
What are the characteristics of Idiopathic Parkinson’s Disease?
- Muscle rigidity
- Tremor (at rest)
- Bradykinesia
- Postural instability
- Shuffling gait
What is the pathophysiology of Idiopathic Parkinson’s Disease?
- death of DA neurons in substantia nigra pars compacta
- Decreased DA in striatum
- (-) direct pathway (which stimulates movement)
- (+) indirect pathway (which inhibits movement)
Levodopa/ Carbidopa (Sinemet)
- IND
Idiopathic Parkinson’s Disease
Levadopa
- MOA
- IND
- SE
- MOA
- Synthesized to DA by LAAD
- need pyridoxine (B6)
- Increase DA in brain
- Synthesized to DA by LAAD
- IND
- IPD
- SE
- Vomiting (DA at area postrema)
- Dyskinesias
- choreathetosis of face, distal extremities
- Psychosis
- Treat with clozapine
- Cardiac dysrhythmias
- metabolism in periphery causes increased catecholamines
- Loss of effect after about 5 years
Carbidopa
- MOA
- IND
- MOA
- inhibits peripheral metabolism of levodopa by inhibiting DOPA decarboxylase
- Decreased side effects in periphery
- increased half life of L-DOPA
- IND
- IPD with L-DOPA treatment
What competes for the same transporter as Levadopa in the GI and can inhibit uptake of the drug?
Amino acids
(absorption by saturable amino acid transporter
Levodopa metabolism
What drug is indicated for psychosis resulting from Levodopa treatment of IPD?
Clozapine
COMT inhibitors (Stalevo)
- MOA
- IND
- SE
- Tolcapone, entacapone
- MOA
- inhibits COMT in the periphery
- increases levodopa in brain
- IND
- IPD when patients start to experience “off” periods to levodopa/ carbidopa
- SE
- Same as levodopa due to increased lvls
- diskinesia
- vomiting
- psychosis
- Same as levodopa due to increased lvls
Non-ergot derivatives, DA agonists
- MOA
- IND
- SE
- MOA
- D2 receptor agonists
- increases the “on” time with levodopa
- inhibits indirect pathway
- D2 receptor agonists
- IND
- IPD (used w/ or w/o levadopa)
- Restless leg syndrome
- SE
- Daytime somnolence
- Sleep attacks
- Hallucinations
- Dyskinesia when used w/ levadopa
- Orthostatic hypotension
Ergot derivatives, DA agonists
- MOA
- IND
- SE
- MOA
- D2 receptor agonist
- IND
- not used in US due to association with valvular heart disease
- SE
- valvular heart disease
- Pulm Fibrosis
- Raynaud-like phenomena
- Orthostatic hypotension
Selegiline
- MOA
- IND
- SE
- MOA
- selective MAO-B inhibitor
- Increased lvls of DA in neuron
- IND
- Parkinsons
- SE
- exacerbate Levodopa SEs
- Insomnia (stimulant metabolite)
- Seizure at high dose
- CON: epilepsy
Benztropine
- MOA
- IND
- SE
- MOA
- M1 receptor antagonist in corpus striatum
- stimulates GABA-ergic outflow
- IND
- Tremor, some rigidity in parkinson’s
- SE
- Antimuscarinic SEs (think atropine)
- Closed Angle Glaucoma
- Neuroleptic Malignant Syndrome
- CNS: sedation, hallucinations
Amantadine
- MOA
- IND
- SE
- MOA
- Stimulates release of DA from neurons of the nigra striatum
- IND
- Diskinesia in late Parkinson’s
- SE
- Anticholinergic
- Livedo reticularis: skin discoloration
What drugs are used for early wearing off of levodopa effect in Parkinson’s?
- Adjust levodopa (change dose, timing)
- Add dopamine agonist
- Add COMT inhibitor, MAO B inhibitor
What is used to treat dyskinesia of Parkinson’s?
- Reduce levodopa dose
- add or increase dopamine agonist
- add amantadine
What is used to treat tremor in Parkinson’s?
Benztropine (M1-receptor antagonist)
What is used to treat freezing in Parkinson’s?
- apomorphine (non-ergot DA agonist)
- orally disintegrating L-dopa
What are the characteristics of dystonias?
- sustained muscle contractions
- twisting and repetitive movements
- abnormal postures
What are the characteristics of spasticity?
Stiff or rigid muscles with exaggerated, deep tendon reflexes
UMN disorder
What drug is used to treat spasticity associated with MS?
Baclofen
Baclofen
- MOA
- IND
- SE
- MOA
- GABA-B receptor agonist
- inhibits reflex at spinal level
- IND
- spasticity associated with MS
- SE
- Sedation
- Withdrawal: seizures and acute psychosis
- CON: spasm from rheumatic disease
Dantrolene
- MOA
- IND
- SE
- MOA
- inhibits Ca2+ release from the sarcoplasmic reticulum in muscle
- decouples excitation - contraction
- muscles relax
- IND
- Spasticity
- Neuroleptic Malignant Syndrome
- Malignant Hyperthermia
- SE
- CNS effects: speech and visual disturbance
- Hepatitis (Hepatotox)
Botulinum Toxin (Botox)
- MOA
- IND
- SE
- MOA
- Toxin
- inhibits vesicle binding to presynaptic membrane
- IND
- Focal dystonia
- Upper limb spasticity
- VII nerve disorders
- SE
- asthenia (weakness)
- Dysphagia and breathing difficulties (treatment of cervical dystonia)
Tizanidine
- MOA
- IND
- SE
- MOA
- centrally-acting alpha-2 adrenergic agonist
- increases presynaptic inhibition of motor neurons
- Less muscle weakness than baclofen and benzodiazepines
- IND
- spasticity
- fibromyalgia
- migraine
- anticonvulsant
- SE
- Hepatotox (hepatitis)
What is the advantage of using Tizanidine to treat spasticity instead of Baclofen?
Less muscle weakness
What are the characteristics of Huntington’s disease?
- Motor Signs
- Chorea
- dysarthria/ dysphagia
- bradykinesia
- Mental:
- personality changes
- Depression
- Dementia
- Psychosis
- Chemical cause:
- Degeneration of GABAergic neurons in the striatum
What drug is used to treat chorea, like that found in Huntington’s disease?
Tetrabenazine
Tetrabenazine
- MOA
- IND
- SE
- MOA
- Inhibits VMAT2 (uptake of monoamines into vesicles)
- Depletes monoamine stores
- IND
- Chorea
- SE
- Sedation
- Insomnia
- Akathisia (restlessness)
- Depression
What are the characteristics of Alzheimer’s Disease? Pathology?
- Signs:
- Loss of memory
- Impaired thinking
- Inability to perform daily tasks
- Path:
- Loss of cholinergic neurons
Donepezil
- MOA
- IND
- SE
- MOA
- AChE inhibitor
- increases ACh at the synapse
- IND
- Alzheimer’s
- improves quality of life but does not slow progression
- SE: Cholinergic effects:
- GI: vomiting, dyspepsia
- CV: syncopy, headache
- Resp: bronchoconstriction
- CNS: tremor, restlessness
Rivastigmine
- MOA
- IND
- SE
- MOA
- AChE inhibitor
- increases ACh at the synapse
- IND
- Alzheimer’s
- improves quality of life but does not slow progression
- SE: Cholinergic effects:
- GI: vomiting, dyspepsia
- CV: syncopy, headache
- Resp: bronchoconstriction
- CNS: tremor, restlessness
Galantamine
- MOA
- IND
- SE
- MOA
- AChE inhibitor
- increases ACh at the synapse
- IND
- Alzheimer’s
- improves quality of life but does not slow progression
- SE: Cholinergic effects:
- GI: vomiting, dyspepsia
- CV: syncopy, headache
- Resp: bronchoconstriction
- CNS: tremor, restlessness
Memantine
- MOA
- IND
- SE
- MOA
- NMDA receptor antagonist
- IND
- moderate to advanced Alzheimer’s
- SE
- headache
- confusion
- constipation
Riluzole
- MOA
- IND
- SE
- MOA
- Decreases glutamate release
- Inhibits Na and Ca channels
- IND
- ALS (lengthens survival)
- SE
- Allergic reaction
- Liver problems
- increased aminotransferases
What drugs are used to treat restless leg syndrome?
- Non-ergot DA agonists
- Praipexole
- Ropinirole
- Gabapentin enacarbil
Gabapentin Enacarbil
- IND
- SE
- IND
- Restless leg syndrome
- SE
- Somnolence
- Sedation
IFN-ß
- MOA
- IND
- SE
- MOA
- anti-inflammatory
- increased integrity of BBB
- IND
- MS
- SE
- Flu-like symptoms
- Hepatotoxicity
- Myelosuppression
- Seizure
- increased Depression and Suicide